Inlyta (axitinib) — United Healthcare
alveolar soft part sarcoma (ASPS)
Initial criteria
- Diagnosis of alveolar soft part sarcoma (ASPS)
- Inlyta will be used in combination with Keytruda (pembrolizumab)
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Inlyta therapy
Approval duration
12 months